Organization: Health Canada
Year: 2023
Month: January
Request Number: A-2022-001005
Request Summary: Adverse Drug Reaction (ADR) for Dexilant. Report number: E2B_05679330. ADR for Entyvio. Report number: E2B_05636147. ADRs for Vedolizumab. Report numbers: E2B_05710173, E2B_05621550, 001006464, E2B_05612446. ADR for Ixazomib. Report number: E2B_05641996. ADR for ADDERALL XR. Report number: 001008189. ADRs for Amphetamine. Report numbers: 001007205, E2B_05661529.
Disposition: Disclosed in part
Number of pages: 366